Inspire Medical Systems Welcomes Michael H. Carrel to Board of Directors
Inspire Medical Systems, Inc. (NYSE: INSP), a leading innovator in medical technology focused on solutions for obstructive sleep apnea (OSA), has announced a significant addition to its leadership team. Effective July 20, 2026, Michael H. Carrel, a seasoned executive in the medical device industry, joins the company’s Board of Directors.
1. A New Era for Inspire Medical Systems
The appointment of Carrel reflects Inspire Medical Systems’ commitment to enhancing its strategic direction and operational excellence. Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems, expressed enthusiasm about Carrel joining the board, highlighting his extensive background in medical devices and executive leadership. “Mike brings extensive executive leadership, board and medical device experience, including a strong track record of developing and commercializing minimally invasive therapies,” Herbert stated. He emphasized the value of Carrel’s guidance as Inspire continues to advance its therapy for patients suffering from OSA.
2. Michael H. Carrel: A Proven Track Record
Carrel brings a wealth of experience to Inspire Medical Systems. He has served as President, Chief Executive Officer, and a director of AtriCure, Inc. (NASDAQ: ATRC) since November 2012. His leadership at AtriCure has been marked by remarkable growth; the company expanded its revenues from $82 million in 2013 to an impressive $535 million by 2025, all while successfully assisting over one million patients.
Prior to his role at AtriCure, Carrel was the Chairman of the Board of Directors at Axonics, Inc. from 2019 until 2024, overseeing the company until its acquisition by Boston Scientific Corporation. His academic credentials include a Bachelor of Science in Accounting from Pennsylvania State University and an MBA from The Wharton School of the University of Pennsylvania.
3. Vision for Inspire Medical Systems
Expressing his excitement about joining Inspire, Carrel noted, “I am excited to join Inspire at this important stage in the Company’s growth. With the recent launch of the fifth-generation Inspire device, a compelling product pipeline, and a growing body of evidence demonstrating the long-term benefits of Inspire therapy, particularly in cardiovascular health, I believe the Company is well positioned to continue expanding access to care for patients with OSA.”
This statement underscores the strategic importance of Inspire's recent innovations as the company seeks to broaden its reach and improve patient outcomes.
4. About Inspire Medical Systems
Inspire Medical Systems is dedicated to the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The company’s proprietary Inspire therapy is the first neurostimulation technology approved by the FDA, EU MDR, and PDMA, providing a safe and effective treatment option for moderate to severe OSA.
As Inspire Medical Systems continues to grow and innovate, the addition of Michael H. Carrel to its Board of Directors marks a pivotal moment in its journey, promising to enhance its capabilities in addressing the challenges faced by OSA patients globally.
For further information about Inspire Medical Systems and its offerings, interested parties are encouraged to visit the company's website at www.inspiresleep.com.
